The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study

Alzheimer's and Dementia

Volumn 13, Issue 9, 2017, Pages 1013-1023

  Bosco, Paolo ^a   Redolfi, Alberto ^a   Bocchetta, Martina ^b   Ferrari, Clarissa ^a   Mega, Anna ^a   Galluzzi, Samantha ^a   Austin, Mark ^c   Chincarini, Andrea ^d   Collins, D Louis ^e,f   Duchesne, Simon ^f   Maréchal, Bénédicte ^g,h,i   Roche, Alexis ^g,h,i   Sensi, Francesco ^d   Wolz, Robin ^c   Alegret, Montserrat ^j   Assal, Frederic ^k   Balasa, Mircea ^l   Bastin, Christine ^m   Bougea, Anastasia ⁿ   Emek Savaş, Derya Durusu ^o   Engelborghs, Sebastiaan ^p,q   Grimmer, Timo ^r   Grosu, Galina ^s   Kramberger, Milica G ^t   Lawlor, Brian ^u   Mandic Stojmenovic, Gorana ^v   Marinescu, Mihaela ^s   Mecocci, Patrizia ^w   Molinuevo, José Luis ^l   Morais, Ricardo ^x   Niemantsverdriet, Ellis ^p   Nobili, Flavio ^y   Ntovas, Konstantinos ^z   O'Dwyer, Sarah ^u   Paraskevas, George P ⁿ   Pelini, Luca ^w   Picco, Agnese ^k,y   Salmon, Eric ^m   Santana, Isabel ^x   Sotolongo Grau, Oscar ^j   Spiru, Luiza ^aa,ab   Stefanova, Elka ^v,ac   Popovic, Katarina Surlan ^t   Tsolaki, Magda ^z   Yener, Görsev G ^o   Zekry, Dina ^k   Frisoni, Giovanni B ^a,k   more..

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IXICO PLC   (United Kingdom)

^d INFN SEZIONE DI GENOVA   (Italy)

^e MCGILL UNIVERSITY   (Canada)

^f True Positive Medical Devices Inc   (Canada)

^g Advanced Clinical Imaging Technology (HC CMEA sui di BM PI)   (Switzerland)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ EPFL   (Switzerland)

^j Inst Catala de Neurociencies Apl   (Spain)

^k UNIVERSITY OF GENEVA   (Switzerland)

^l HOSPITAL CLÍNIC   (Spain)

^m UNIVERSITY OF LIÈGE   (Belgium)

ⁿ UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^o DOKUZ EYLUL UNIVERSITY   (Turkey)

^p UNIVERSITY OF ANTWERP   (Belgium)

^q Hospital Network Antwerp (ZNA) Hoge Beuken and Middelheim   (Belgium)

^r TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^s Emergency Hospital   (Romania)

^t UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^u ST JAMES S HOSPITAL   (Ireland)

^v CCS   (Serbia)

^w UNIVERSITY OF PERUGIA   (Italy)

^x CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^y UNIVERSITY OF GENOA   (Italy)

^z ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^aa CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^ab Gerontology and Geriatrics   (Romania)

^ac UNIVERSITY OF BELGRADE   (Serbia)

more..

Author keywords

Alzheimer's disease; Biomarkers; Diagnostic confidence of AD; Hippocampal volume; Medial temporal lobe atrophy

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLUORODEOXYGLUCOSE F 18; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOMATED HIPPOCAMPAL VOLUMETRY; AUTOMATION; BRAIN ATROPHY; BRAIN SCINTISCANNING; BRAIN SIZE; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COGNITIVE DEFECT; DIAGNOSTIC VALUE; EXECUTIVE FUNCTION TEST; FEMALE; HIPPOCAMPUS; HUMAN; IMAGE SEGMENTATION; LANGUAGE TEST; LONG TERM MEMORY; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MEDIAL TEMPORAL LOBE; MEMORY TEST; MINI MENTAL STATE EXAMINATION; NERVE BIOPSY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; VISUAL-SPATIAL ABILITY TEST; VOLUMETRY; CLINICAL TRIAL; COMPLICATION; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; EUROPE; METABOLISM; MULTICENTER STUDY; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COGNITION DISORDERS; DIAGNOSIS, COMPUTER-ASSISTED; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EUROPE; FEMALE; FLUORODEOXYGLUCOSE F18; HIPPOCAMPUS; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 85014782159     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2017.01.019     Document Type: Article

References (39)

1. Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 280–292.
2. Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 270–279.
3. McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 263–269.
4. Dubois, B., Feldman, H.H., Jacova, C., Dekosky, S.T., Barberger-Gateau, P., Cummings, J., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6 (2007), 734–746.
5. Dubois, B., Feldman, H.H., Jacova, C., Cummings, J.L., Dekosky, S.T., Barberger-Gateau, P., et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9 (2010), 1118–1127.
6. Scheltens, P., Leys, D., Barkhof, F., Huglo, D., Weinstein, H.C., Vermersch, P., et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55 (1992), 967–972.
7. Jack, C.R., Alliance for aging research AD biomarkers work group: structural MRI. Neurobiol Aging 32 Suppl 1 (2011), S48–S57.
8. Frisoni, G.B., Hampel, H., O'Brien, J.T., Ritchie, K., Winblad, B., Revised criteria for Alzheimer's disease: what are the lessons for clinicians?. Lancet Neurol 10 (2011), 598–601.
9. Frisoni, G.B., Bocchetta, M., Chételat, G., Rabinovici, G.D., de Leon, M.J., Kaye, J., et al. Imaging markers for Alzheimer disease: which vs how. Neurology 81 (2013), 487–500.
10. Hampel, H., Lista, S., Teipel, S.J., Garaci, F., Nisticò, R., Blennow, K., et al. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochem Pharmacol 88 (2014), 426–449.
11. Shaffer, J.L., Petrella, J.R., Sheldon, F.C., Choudhury, K.R., Calhoun, V.D., Coleman, R.E., et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology 266 (2013), 583–591.
12. Prestia, A., Caroli, A., Herholz, K., Reiman, E., Chen, K., Jagust, W.J., et al. Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimers Dement 9 (2013), 677–686.
13. Choo, I.H., Ni, R., Schöll, M., Wall, A., Almkvist, O., Nordberg, A., Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients. J Alzheimers Dis 33 (2013), 929–939.
14. Prestia, A., Caroli, A., van der Flier, W.M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 80 (2013), 1048–1056.
15. Prestia, A., Caroli, A., Wade, S.K., Van Der Flier, W.M., Ossenkoppele, R., Van Berckel, B., et al. Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimers Dement 11 (2015), 1191–1201.
16. Engelborghs, S., De Vreese, K., Van de Casteele, T., Vanderstichele, H., Van Everbroeck, B., Cras, P., et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29 (2008), 1143–1159.
17. Apostolova, L.G., Zarow, C., Biado, K., Hurtz, S., Boccardi, M., Somme, J., et al. Relationship between hippocampal atrophy and neuropathology markers: a 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol. Alzheimers Dement 11 (2015), 139–150.
18. Bocchetta, M., Boccardi, M., Ganzola, R., Apostolova, L.G., Preboske, G., Wolf, D., et al. Harmonized benchmark labels of the hippocampus on magnetic resonance: the EADC-ADNI project. Alzheimers Dement 11 (2015), 151–160.e5.
19. Jack, C.R., Barkhof, F., Bernstein, M.A., Cantillon, M., Cole, P.E., Decarli, C., et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement 7 (2011), 474–485.e4.
20. Frisoni, G.B., Jack, C.R., Bocchetta, M., Bauer, C., Frederiksen, K.S., Liu, Y., et al. The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. Alzheimers Dement 11 (2015), 111–125.
21. Jack, C.R., Bernstein, M.A., Fox, N.C., Thompson, P., Alexander, G., Harvey, D., et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 27 (2008), 685–691.
22. Morra, J.H., Tu, Z., Apostolova, L.G., Green, A.E., Avedissian, C., Madsen, S.K., et al. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage 43 (2008), 59–68.
23. Fischl, B., Salat, D.H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33 (2002), 341–355.
24. Wolz, R., Aljabar, P., Hajnal, J.V., Hammers, A., Rueckert, D., LEAP: learning embeddings for atlas propagation. Neuroimage 49 (2010), 1316–1325.
25. Chincarini, A., Sensi, F., Rei, L., Gemme, G., Squarcia, S., Longo, R., et al. Integrating longitudinal information in hippocampal volume measurements for the early detection of Alzheimer's disease. Neuroimage 125 (2015), 834–847.
26. Collins, D.L., Pruessner, J.C., Towards accurate, automatic segmentation of the hippocampus and amygdala from MRI by augmenting ANIMAL with a template library and label fusion. Neuroimage 52 (2010), 1355–1366.
27. Hu, S., Coupé, P., Pruessner, J.C., Collins, D.L., Nonlocal regularization for active appearance model: application to medial temporal lobe segmentation. Hum Brain Mapp 35 (2014), 377–395.
28. Roche, A., Ribes, D., Bach-Cuadra, M., Krüger, G., On the convergence of EM-like algorithms for image segmentation using Markov random fields. Med Image Anal 15 (2011), 830–839.
29. Schmitter, D., Roche, A., Maréchal, B., Ribes, D., Abdulkadir, A., Bach-Cuadra, M., et al. An evaluation of volume-based morphometry for prediction of mild cognitive impairment and Alzheimer's disease. Neuroimage Clin 7 (2015), 7–17.
30. Redolfi, A., McClatchey, R., Anjum, A., Zijdenbos, A., Manset, D., Barkhof, F., et al. Grid infrastructures for computational neuroscience: the neuGRID example. Future Neurol 4 (2009), 703–722.
31. Frisoni, G.B., Redolfi, A., Manset, D., Rousseau, M.É., Toga, A., Evans, A.C., Virtual imaging laboratories for marker discovery in neurodegenerative diseases. Nat Rev Neurol 7 (2011), 429–438.
32. Groeneveld, R.A., Meeden, G., Measuring skewness and kurtosis. J R Stat Soc Ser D 33 (1984), 391–399.
33. Ferrari, S., Cribari-Neto, F., Beta regression for modelling rates and proportions. J Appl Stat 31 (2004), 799–815.
34. Cepeda-Cuervo, E., Beta regression models: joint mean and variance modeling. J Stat Theory Pract 9 (2014), 134–145.
35. Gelman, A., Pardoe, I., Bayesian measures of explained variance and pooling in multilevel (hierarchical) models. Technometrics 48 (2006), 241–251.
36. Gelman, A., Rubin, D.B., Inference from iterative simulation using multiple sequences. Stat Sci 7 (1992), 457–511.
37. Bocchetta, M., Galluzzi, S., Kehoe, P.G., Aguera, E., Bernabei, R., Bullock, R., et al. The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. Alzheimers Dement 11 (2015), 195–206.e1.
38. Johnson, K.A., Minoshima, S., Bohnen, N.I., Donohoe, K.J., Foster, N.L., Herscovitch, P., et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement, 9, 2013 e-1–16.
39. Grundman, M., Pontecorvo, M.J., Salloway, S.P., Doraiswamy, P.M., Fleisher, A.S., Sadowsky, C.H., et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord 27 (2013), 4–15.